Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203580 | 0.83 | CYP2C19 (0.36) | NAAACYP2C19HTT | |
| SCHEMBL13464632 | 0.78 | MMP1 (0.37) | CYP2C19 | |
| SCHEMBL3819860 | 0.76 | MMP1 (0.40) | — | |
| SCHEMBL605383 | 0.73 | MMP1 (0.42) | — | |
| SCHEMBL605384 | 0.73 | MMP1 (0.42) | — | |
| SCHEMBL6979479 | 0.73 | CYP2C19 (0.33) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL385321 | 0.72 | GNAI3 (0.34) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL385319 | 0.72 | GNAI3 (0.34) | CYP2C19 | |
| SCHEMBL605108 | 0.71 | CYP2C19 (0.34) | CYP2C19 | |
| SCHEMBL1834809 | 0.71 | CYP1A2 (0.36) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-13 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | NAAA 647/4885CYP2C19 141/4885HTT 3531/4885 |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | NAAA 647/4885CYP2C19 141/4885HTT 3531/4885 |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | NAAA 1472/4885CYP2C19 708/4885HTT 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.